Recce Pharmaceuticals (ASX:RCE) Presentation, FNN Investor Event, September 2019, Sydney

Company Presentations

Recce Pharmaceuticals Limited (ASX:RCE) Executive Director, James Graham presents on the company's lead product RECCE 327, including significant progress with manufacturing, securing patents and presenting to a global audience, at FNN's Investor Event.

Key points:

  • Recce Pharmaceuticals is commercialising a new class of broad-spectrum synthetic antibiotics to address the global health issue of antibiotic-resistant superbugs, including sepsis, which affects 30 million+ people worldwide
  • New class of broad spectrum antibiotics that kill Gram + and Gram bacteria, including their superbug forms -- even with repeated use
  • #1 most expensive condition. Sepsis: $24bn in annual costs treated in US hospitals
  • Qualified Infectious Disease Product designation under GAIN Act. 10 years of market exclusivity (post-approval). Fast track (life of the regulatory process). Patented manufacturing, producing to Phase I & II volumes.
  • Synthetic antibiotics, entirely man-made and designed with purpose, universal Mechanism of Action - detailed experimentation demonstrates it does not succumb to superbugs

For more, watch Executive Director, James Graham present.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.